Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

kelly smith

The Medscape Medical Affairs Difference

What is so different about Medscape Medical Affairs in this crowdedMedical Communications landscape?

Medscape Medical Affairs

- PMLiVE

Leveraging KOL insights to succeed in a data-driven world

For years, key opinion leaders (KOLs) have held a position of authority and respect amongst those working across the life science industry, be it a result of their expertise in...

Medscape Medical Affairs

an image of an older lady receiving medicine

MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE

With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is...

Wilmington Healthcare

- PMLiVE

Customers, content and change

By Dominic Tyer

- PMLiVE

FlyPharma Conference Europe 2022 shares the latest supply chain challenges and advice for better industry collaboration

Leipzig, Germany was the chosen host city for the live, in-person event

- PMLiVE

Shionogi signs licence agreement with MPP for COVID-19 oral antiviral treatment

The agreement aims to increase access to ensitrelvir in low- and middle-income countries

- PMLiVE

Pfizer’s Talzenna combination treatment meets primary endpoint in phase 3 prostate cancer study

An improvement in radiographic progression-free survival was demonstrated

- PMLiVE

Boehringer Ingelheim and HeartBeat.bio partner to accelerate heart disease treatments

Heart and circulatory diseases cause over 160,000 deaths in the UK each year

- PMLiVE

Novo Nordisk’s insulin icodec shows promise as once-weekly type 2 diabetes treatment

Currently, the basal insulin products with the longest duration are injected once daily

- PMLiVE

The Holy Grail of healthcare pricing

By Rohit Khanna

- PMLiVE

Incyte to acquire Villaris Therapeutics to expand inflammation and autoimmunity portfolio

Auremolimab, which has proven efficacy for vitiligo, is included in the deal

- PMLiVE

Biogen and Denali dose first patients with LRRK2 inhibitor in Parkinson’s disease study

Mutations in the LRRK2 gene are one of the most common causes of familial Parkinson’s disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links